Patents by Inventor Andrew J. Tebben

Andrew J. Tebben has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SUBSTITUTED OXOISOINDOLINE COMPOUNDS FOR THE TREATMENT OF CANCER
    Publication number: 20230322803
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
    Type: Application
    Filed: March 22, 2021
    Publication date: October 12, 2023
    Inventors: Andrew P. Degnan, Godwin Kwame Kumi, Andrew J. Tebben, Audris Huang, Peter Kinam Park, Donna M. Bilder, Emily Charlotte Cherney, Ashok Vinayak Purandare
  • TGF Beta RECEPTOR ANTAGONISTS
    Publication number: 20190292179
    Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: July 19, 2017
    Publication date: September 26, 2019
    Inventors: Robert M. Borzilleri, Peiyung Liu, Andrew J. Tebben, Upender Velaparthi, Hasibur Rahaman, Gopikishan Tonukunuru, Jayakumar Sankara Warrier
  • Tricyclic heterocyclic compounds useful as inhibitors of TNF
    Patent number: 10308652
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: June 4, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Stephen T. Wrobleski, Gregory D. Brown, Shuqun Lin, Jingwu Duan, Zhonghui Lu, Murali T. G. Dhar, Hai-Yun Xiao, Andrew J. Tebben
  • Substituted tricyclic heterocyclic compounds
    Patent number: 10189840
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: (i) —(CR3R3)1-4—; (ii) —(CR3R3)x—Y—(CR3R3)y—; Or (iii) —Y—(CR3R3)2—Y—; and Y, R1, R2, R3, R5, R6, R8, x, and y are defined herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Grant
    Filed: March 17, 2016
    Date of Patent: January 29, 2019
    Assignee: Bristol-Myers Squibb Company
    Inventors: Hai-Yun Xiao, Murali T. G. Dhar, Jingwu Duan, Bin Jiang, Andrew J. Tebben
  • Carbazole and tetrahydrocarbazole compounds useful as inhibitors of BTK
    Patent number: 10023534
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein Q is: or; and X, R1a, R1b, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: July 17, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Scott Hunter Watterson, Andrew J. Tebben, Saleem Ahmad
  • SUBSTITUTED TRICYCLIC HETEROCYCLIC COMPOUNDS
    Publication number: 20180111936
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: (i) —(CR3R3)1-4—; (ii) —(CR3R3)x—Y—(CR3R3)y—; Or (iii) —Y—(CR3R3)2—Y—; and Y, R1, R2, R3, R5, R6, R8, x, and y are defined herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 17, 2016
    Publication date: April 26, 2018
    Inventors: Hai-Yun XIAO, Murali T.G. DHAR, Jingwu DUAN, Bin JIANG, Andrew J. TEBBEN
  • TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF
    Publication number: 20180111937
    Abstract: Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: —(CR3R3)2-5-, —(CR3R3)x-Y—(CR3R3)y-, —Y—(CR3R3)2-3-Y—, —CR3R3-Y—(CR3R3)2-Y—, —Y—(CR3R3)2-Y—CR3R3-; and Y, R1, R2, R3, R5, R6, R8, x, and y are define herein. Also disclosed are methods of using such compounds as modulators of TNF?, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.
    Type: Application
    Filed: March 17, 2016
    Publication date: April 26, 2018
    Inventors: Stephen T. WROBLESKI, Gregory D. BROWN, Shuqun LIN, Jingwu DUAN, Zhonghui LU, Murali T.G. DHAR, Hai-Yun XIAO, Andrew J. TEBBEN
  • Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
    Patent number: 9902740
    Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 27, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong Zhang, Robert M. Borzilleri, Andrew J. Tebben, Erik M. Stang, Andrew F. Donnell, Gretchen M. Schroeder, Heidi L. Perez, Donna D. Wei
  • TRICYCLIC ATROPISOMER COMPOUNDS
    Publication number: 20170355673
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein Q is: or; and X, R1a, R1b, R3, R4, and R5 are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: October 23, 2015
    Publication date: December 14, 2017
    Inventors: Scott Hunter Watterson, Andrew J. Tebben, Saleem Ahmad
  • Indole carboxamide compounds
    Patent number: 9802915
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: October 31, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Qingjie Liu, Scott Hunter Watterson, Saleem Ahmad, Andrew J. Tebben
  • MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES
    Publication number: 20170260205
    Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).
    Type: Application
    Filed: May 26, 2017
    Publication date: September 14, 2017
    Inventors: Yong ZHANG, Robert M. BORZILLERI, Andrew J. TEBBEN, Erik STANG, Andrew F. DONNELL, Gretchen M. SCHROEDER, Heidi L. PEREZ, Donna D. WEI
  • INDOLE CARBOXAMIDE COMPOUNDS
    Publication number: 20170260160
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: May 30, 2017
    Publication date: September 14, 2017
    Inventors: Qingjie Liu, Scott Hunter Watterson, Douglas G. Batt, Saleem Ahmad, Myra Beaudoin Bertrand, Hua Gong, Weiwei Guo, John E. Macor, Khehyong Ngu, Andrew J. Tebben, Joseph A. Tino
  • TGF?R antagonists
    Patent number: 9708316
    Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Grant
    Filed: December 22, 2015
    Date of Patent: July 18, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Brian E. Fink, Yufen Zhao, Robert M. Borzilleri, Liping Zhang, Kyoung S. Kim, Muthoni G. Kamau, Andrew J. Tebben, Yong Zhang, Andrew F. Donnell
  • Macrocyclic benzodiazepine dimers, conjugates thereof, preparation and uses
    Patent number: 9688694
    Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).
    Type: Grant
    Filed: June 22, 2016
    Date of Patent: June 27, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Yong Zhang, Robert M. Borzilleri, Andrew J. Tebben, Erik M. Stang, Andrew F. Donnell, Gretchen M. Schroeder, Heidi L. Perez, Donna D. Wei
  • INDOLE CARBOXAMIDE COMPOUNDS
    Publication number: 20170066740
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: November 17, 2016
    Publication date: March 9, 2017
    Inventors: Qingjie Liu, Scott Hunter Watterson, Saleem Ahmad, Andrew J. Tebben
  • MACROCYCLIC BENZODIAZEPINE DIMERS, CONJUGATES THEREOF, PREPARATION AND USES
    Publication number: 20160376288
    Abstract: Macrocyclic benzodiazepine dimers having a structure represented by formula I where A and B are independently according to formulae Ia or Ib and the other variables in formulae I, Ia, and Ib are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used as the drug component in an antibody-drug conjugate (ADC).
    Type: Application
    Filed: June 22, 2016
    Publication date: December 29, 2016
    Inventors: Yong ZHANG, Robert M. BORZILLERI, Andrew J. TEBBEN, Erik M. STANG, Andrew F. DONNELL, Gretchen M. SCHROEDER, Heidi L. PEREZ, Donna D. WEI
  • TGF BETA R ANTAGONISTS
    Publication number: 20160176871
    Abstract: The invention relates generally to compounds that modulate the activity of TGF?R-1 and TGF?R-2, pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.
    Type: Application
    Filed: December 22, 2015
    Publication date: June 23, 2016
    Inventors: Brian E. Fink, Yufen Zhao, Robert M. Borzilleri, Liping Zhang, Kyoung S. Kim, Muthoni G. Kamau, Andrew J. Tebben
  • Substituted sulfonamides useful as antiapoptotic Bcl inhibitors
    Patent number: 9346795
    Abstract: Disclosed are compounds of Formula (I), or a pharmaceutically acceptable salt thereof, wherein: W and Q and G are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bcl-2 family antiapoptotic proteins for the treatment of cancer; and pharmaceutical compositions comprising such compounds.
    Type: Grant
    Filed: May 23, 2012
    Date of Patent: May 24, 2016
    Assignee: Bristol-Myers Squibb Company
    Inventors: Robert M. Borzilleri, Zhen-Wei Cai, Andrew J. Tebben, Heidi L. Perez, Liping Zhang, Gretchen M. Schroeder, Donna D. Wei
  • INDOLE CARBOXAMIDE COMPOUNDS
    Publication number: 20160115126
    Abstract: Disclosed are compounds of Formula (I): or a salt thereof, wherein: X is CR4 or N; R1, R2, R3, R4, and A are defined herein. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: October 23, 2015
    Publication date: April 28, 2016
    Inventors: Qingjie Liu, Scott Hunter Watterson, Douglas G. Batt, Saleem Ahmad, Myra Beaudoin Bertrand, Hua Gong, Weiwei Guo, John E. Macor, Khehyong Ngu, Andrew J. Tebben, Joseph A. Tino
  • Benzylpyrrolidinone derivatives as modulators of chemokine receptor activity
    Patent number: 9040526
    Abstract: The present application describes modulators of MCP-1 or CCR-2 of formula or stereoisomers or prodrugs or pharmaceutically acceptable salts thereof, wherein m, n, W, X, R1 and R6, are defined herein. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and transplant rejection using modulators of formula (I) are disclosed.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: May 26, 2015
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ian K. Mangion, Percy H. Carter, Jingwu Duan, Andrew J. Tebben